Aytu BioPharma (NASDAQ:AYTU) Announces Earnings Results

Aytu BioPharma (NASDAQ:AYTU) announced its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.24, Zacks reports. Aytu BioPharma had a negative net margin of 60.17% and a negative return on equity of 69.93%. The firm had revenue of $16.11 million for the quarter, compared to the consensus estimate of $12.28 million.

Aytu BioPharma Price Performance

NASDAQ AYTU traded up $0.10 during trading on Tuesday, hitting $2.23. 246,930 shares of the company’s stock were exchanged, compared to its average volume of 48,834. The company has a market cap of $23.93 million, a PE ratio of -0.49 and a beta of 0.26. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 0.27. Aytu BioPharma has a fifty-two week low of $1.65 and a fifty-two week high of $3.07. The stock’s 50 day moving average price is $2.21 and its two-hundred day moving average price is $2.33.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aytu BioPharma in a report on Monday, July 6th. Ascendiant Capital Markets boosted their price objective on shares of Aytu BioPharma from $14.00 to $14.50 and gave the company a “buy” rating in a research report on Thursday, June 11th. Finally, Zacks Research upgraded Aytu BioPharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $10.75.

Aytu BioPharma Company Profile

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on commercializing prescription medicines, primarily for pediatric and primary-care markets. The company’s activities include acquiring, developing and commercializing products intended to address unmet needs in areas such as attention deficit hyperactivity disorder (ADHD), allergies and other common medical conditions.

Aytu’s ADHD portfolio has included Adzenys XR-ODT, an orally disintegrating extended-release amphetamine tablet; Cotempla XR-ODT, an orally disintegrating extended-release methylphenidate tablet; and Dyanavel XR, an extended-release liquid amphetamine formulation.